JPMorgan lowered the firm’s price target on Vistra (VST) to $186 from $203 and keeps an Overweight rating on the shares. The firm says that ...

While maintaining a balanced diet is of the utmost importance, she adds that “Supplements can achieve adequate levels of nutrients, such as low vitamin D and iron, quicker than natural sources ...

All kinds of cells in your body need vitamin B12. That includes red blood cells and glial cells – the kind that protect your nerves. But your body doesn't make this nutrient on its own.

Kennedy Jr. promoted the Centers for Disease Control and Prevention's recommendations on vitamin A to treat the measles infection. But there is a big difference between treating an illness and ...

While I like to keep my skincare routine simple, there are certain ingredients that are non-negotiable for me when it comes to choosing products—and vitamin C is one of those. Truly, not a morni ...

Deep-pocketed investors have adopted a bullish approach towards Vistra VST, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Vistra is navigating a challenging period as a series of recent developments have impacted its share price, which experienced a 14% decline last week. The announcement of their 2025 earnings ...

Breastfed infants and children with certain medical conditions are also susceptible to vitamin D deficiency. If a healthcare professional has recommended a vitamin D supplement for calcium ...

You probably have that friend who swears by the vitamin regimen they take every morning. Maybe they've even bragged about their newfound energy, glowing skin, and super-strong immune system.

The negative setback may prove temporary, and Vistra has the potential to deliver a major deal with a cloud service provider to service its AI-driven power needs. The stock price fall coincides ...

Daiwa initiated coverage of Vistra (VST) with a Neutral rating and $120 price target Vistra is a “great” artificial intelligence story, but this is already in the share price, the analyst ...